NEW YORK, May 11 (GenomeWeb News) - Transgenomic today reported a drop in first-quarter earnings, accompanied by widening net losses and reduced R&D spending.

Transgenomic's revenues for the quarter ended March 31, 2004, were $8.6 million, down 9 percent from $9.5 million in the first quarter of 2004. CEO Collin D'Silva said that revenue from sales of bioconsumables during the quarter increased 35 percent year-over-year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.